by 
The global angioedema treatment market has witnessed substantial growth in recent years owing to the increasing prevalence of the disease globally. Angioedema refers to painful swelling that occurs underwater layers of the skin in any body part, including the face, hands, feet, genitals, digestive tract, or throat. Angioedema drugs help to control swelling and relieve symptoms. C1 esterase inhibitor, a plasma-derived C1-inhibitor product, is the treatment of choice for frequent or severe hereditary angioedema attacks. Additionally, androgens and antifibrinolytics like tranexamic acid and epsilon-aminocaproic acid are used to prevent and reduce HAE attacks.
The Global Angioedema Treatment Market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.
Key Takeaways
Key players: Key players operating in the angioedema treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd.
Growing demand: There is an increasing demand for angioedema treatment drugs due rising cases of hereditary and acquired angioedema globally. According to studies, approximately 1 in 10,000 to 1 in 50,000 people suffer from hereditary angioedema.
Global expansion: Major players are focusing on geographical expansion plans in emerging countries by collaborating with regional pharma companies to distribute their treatment drugs for better access and market penetration.
Market key trends
Increasing healthcare expenditure: High healthcare expenditure in developed nations has enabled improved access to advanced treatment options driving the angioedema treatment market growth globally. Countries are spending more on rare disease treatment.
Development of novel drugs: Drug manufacturers are continuously investing in R&D to develop more effective and targeted treatment drugs to cure angioedema with lesser side effects. Several pipeline drugs are under development and trials.
Porter’s Analysis
Threat of new entrants: High capital requirements and existence of major players pose significant entry barriers for newcomers in this market.
Bargaining power of buyers: Large pharmaceutical companies and availability of generic alternatives increase negotiating power of buyers in this market.
Bargaining power of suppliers: Established supply networks and regulatory processes make it difficult for suppliers to influence prices in this market.
Threat of new substitutes: Limited research into new treatment options poses low threat of substitution in angioedema treatment market currently.
Competitive rivalry: Significant research and marketing expenditures by top players and patented drug brands increase competitive intensity in this market.
Geographical Regions
North America currently accounts for the largest share of the global angioedema treatment market, primarily due to high incidence of angioedema, strong healthcare infrastructure, and affordability of treatment options in the region.
Asia Pacific region is poised to be the fastest growing market for angioedema treatment during the forecast period, owing to rising medical expenditures, growing patient awareness, and increasing penetration of global pharmaceutical companies in major Asian countries.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
